Eyenovia Inc (NASDAQ:EYEN) Expected to Announce Earnings of -$0.41 Per Share

Brokerages predict that Eyenovia Inc (NASDAQ:EYEN) will post earnings of ($0.41) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Eyenovia’s earnings, with the lowest EPS estimate coming in at ($0.48) and the highest estimate coming in at ($0.34). Eyenovia posted earnings of ($0.43) per share during the same quarter last year, which suggests a positive year over year growth rate of 4.7%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, November 12th.

According to Zacks, analysts expect that Eyenovia will report full-year earnings of ($1.73) per share for the current financial year, with EPS estimates ranging from ($2.00) to ($1.55). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.33) per share, with EPS estimates ranging from ($1.77) to ($1.05). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Eyenovia.

Eyenovia (NASDAQ:EYEN) last released its earnings results on Monday, August 12th. The company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.03.



A number of equities research analysts recently weighed in on EYEN shares. HC Wainwright set a $14.00 price objective on shares of Eyenovia and gave the company a “buy” rating in a research report on Wednesday, June 5th. Zacks Investment Research upgraded shares of Eyenovia from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research report on Friday, August 16th. Finally, ValuEngine upgraded shares of Eyenovia from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

In other news, CEO Tsontcho Ianchulev bought 233,813 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was purchased at an average price of $2.78 per share, for a total transaction of $650,000.14. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Curt H. Labelle bought 17,985 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was purchased at an average price of $2.78 per share, with a total value of $49,998.30. The disclosure for this purchase can be found here. 43.10% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp bought a new position in Eyenovia in the 4th quarter worth about $36,000. Vanguard Group Inc. grew its position in Eyenovia by 72.4% in the 2nd quarter. Vanguard Group Inc. now owns 139,748 shares of the company’s stock worth $601,000 after purchasing an additional 58,697 shares during the last quarter. Finally, Uniplan Investment Counsel Inc. grew its position in Eyenovia by 22.4% in the 2nd quarter. Uniplan Investment Counsel Inc. now owns 544,896 shares of the company’s stock worth $2,343,000 after purchasing an additional 99,896 shares during the last quarter. Hedge funds and other institutional investors own 8.08% of the company’s stock.

Shares of NASDAQ:EYEN traded up $0.01 during trading on Friday, reaching $3.15. 16,721 shares of the company’s stock traded hands, compared to its average volume of 68,957. Eyenovia has a 12 month low of $2.40 and a 12 month high of $6.98. The company has a 50 day moving average of $3.26 and a 200-day moving average of $4.84. The stock has a market capitalization of $52.61 million, a P/E ratio of -1.73 and a beta of 1.11.

Eyenovia Company Profile

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

See Also: Percentage Decliners

Get a free copy of the Zacks research report on Eyenovia (EYEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eyenovia (NASDAQ:EYEN)

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.